Zydus receives EIR for oncology injectable manufacturing facility in Ahmedabad SEZ1
The facility has been classified as Voluntary Action Indicated
The facility has been classified as Voluntary Action Indicated
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Subscribe To Our Newsletter & Stay Updated